Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

Biotech Advances in South Dakota

Biotech Advances in South Dakota

Last week I made my first visit to our South Dakota affiliate. The South Dakota Biotech Association, formed in 2006, held its fourth annual conference on Thursday, September 17th. I began my tour on Wednesday at Hematech, Inc.   The company, headquartered in Sioux Falls, is developing cattle that can efficiently produce human antibodies.  The genetically altered cattle will be used for the production of large quantities of polyclonal antibodies.  These antibodies are expected to help Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Touring Local Biotech Companies with Former Governor Dean

Touring Local Biotech Companies with Former Governor Dean

Last week I spent a fascinating day with former Vermont Governor Howard Dean and three Members of the Maryland Congressional delegation.  First, along with local Congressman Roscoe Bartlett (R, MD-6), we visited MedImunne’s brand new biologic manufacturing facility in Frederick. The half billion dollar facility is nearly complete and will employ 350 people manufacturing the company’s monoclonal antibody, Synagis. This product helps prevent lower respiratory disease from a common virus which in vulnerable children, particularly Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Jim Greenwood guest appearance on CNBC’s “Squawk Box” during this morning’s “Health Care Summit” special

BIO President and CEO Jim Greenwood joined former HHS Secretary Tommy Thompson and former FDA Deputy Commissioner Scott Gottlieb to discuss biosimilars and the importance of preserving innovation as the nation moves to reform our health care system.

Jim's Corner  |  Leave a comment  |  Email This Post

Clearing Another Hurdle on the Pathway to Biosimilars

The House Energy and Commerce Committee, by a vote of 47 to 11, overwhelmingly adopted an amendment creating a regulatory pathway for biosimilars that will provide 12 years of data exclusivity for innovative biologics. The strong bipartisan support for this amendment to the America’s Affordable Health Choices Act marks the second win this month for a fair and balanced approach to biosimilars market entry. This vote was a clear victory for patients. The ALS Association Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Patient groups join call for data protection

Biomedical innovation is not only key to our industry’s future, but more importantly, continued medical breakthroughs are vital to patients living with debilitating diseases and their families. Without ongoing progress in our industry, patients of today and tomorrow have limited hope for future cures and therapies. Many patient groups have entered the debate on Capitol Hill over establishing a pathway for approval of biosimilars because they know how critical continued innovation is to finding new Read More >

Jim's Corner  |  Leave a comment  |  Email This Post